Document is current
Any future updates will be listed below
-
Authors
Tsai, Katy K.
Komanduri, Krishna V. https://orcid.org/0000-0003-3715-5236
- License Information
-
More Information
Article History
Accepted: 24 May 2025
First Online: 23 June 2025
Declarations
:
: No external funding was used in the preparation of this article.
: Katy K. Tsai has received consulting honoraria from BMS and Regeneron and institutional research funding from ABM Therapeutics, AstraZeneca, BioAtla, BMS, Genentech, Georgiamune, Ideaya Biosciences, Innovent, OnKure, Pfizer, Replimune, and Regeneron. Krishna V. Komanduri has provided ad hoc consulting for BMS, Cargo Therapeutics, CRISPR Therapeutics, Genentech/Roche, Incyte, Iovance and Sanofi and is a scientific advisory board member for Aegle Therapeutics and CellChorus.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this review article as no new data were created or analyzed.
: Not applicable.
: Both K.K.T. and K.V.K. contributed to the conception, writing and editing of the manuscript.
